Gossamer Bio's Future Hangs in Balance After Drug Trial Failure

Gossamer Bio faces uncertainty after its key drug, seralutinib, failed a critical Phase 3 trial in February 2026. The setback has sent its stock tumbling, with shares now trading at around $0.42—a drop of roughly 86% since January. Investors and analysts are watching closely as the biotech firm prepares for a crucial meeting with US regulators.

The failure of seralutinib, also known as PROSERA, marks a major blow for Gossamer Bio. Designed to treat pulmonary arterial hypertension (PAH), the drug's poor trial results have thrown its entire development programme into doubt. In response, the company has scheduled a 'Type C' meeting with the FDA in June to explore potential paths forward. A decision on whether the project can continue is expected by July.

Financial analysts have reacted sharply to the news. Cantor Fitzgerald downgraded the stock from 'Overweight' to 'Neutral' shortly after the trial results were announced. Other firms, including Barclays and Wedbush, had already cut their forecasts for Gossamer Bio in late February. Opinions remain split, with two analysts advising investors to sell, while four still recommend buying—though their price targets vary widely, from $0.30 to $15.00. The company's market value has shrunk dramatically, now standing at just $99 million. With quarterly earnings due on May 12, shareholders will be looking for clarity on how Gossamer Bio plans to navigate this crisis. The FDA's feedback later this summer will be critical in determining whether seralutinib has any future.

Gossamer Bio's next steps depend heavily on the FDA's June meeting and the subsequent decision in July. The failed trial has already triggered steep stock declines and divided analyst opinions. The company's upcoming earnings report on May 12 may offer further insight into its financial position and strategy moving forward.